眼科領域におけるNY-198の臨床的・基礎的検討
書誌事項
- タイトル別名
-
- BASIC AND CLINICAL STUDIES ON NY-198 IN OPHTHALMOLOGY
抄録
We performed basic and clinical studies on NY-198, a new quinoline derivative for oral use, in the field of ophthalmology.<BR>1) NY-198 was administered orally in a daily dose of 300mg or 600mg to 17 patients with various eye infections, including hordeolum 6, acute dacryocystitis 2, meibomitis 7, corneal ulcer 1, and lid abscess 1. Clinical results were excellent in 10, good in 6, and fair in 1, the total efficacy rate being 94.4%.<BR>2) We measured NY-198 concentrations in both serum and tear fluid 0.5, 1.0, 2.0, 3.0, 4.0, and 6.0 hours after a single oral dose of 200mg. The average peak serum and tear levels were 1.25μg/ml±0.14 and 0.98μg/ml±0.27 at 2 h after treatment. This tear level was considered effective in external eye infections (meibomitis, hordeolum, dacryocystitis, etc.) caused byS. aureus.<BR>3) No side-effects or abnormal clinical laboratory findings due to NY-198 were observed, with the exception of stomach-ache in one patient.
収録刊行物
-
- CHEMOTHERAPY
-
CHEMOTHERAPY 36 (Supplement2-Clinical), 1336-1340, 1988
公益社団法人 日本化学療法学会
- Tweet
詳細情報 詳細情報について
-
- CRID
- 1390282681262821632
-
- NII論文ID
- 130004196094
-
- ISSN
- 18845894
- 00093165
-
- データソース種別
-
- JaLC
- CiNii Articles
-
- 抄録ライセンスフラグ
- 使用不可